GeoVax Labs (NASDAQ:GOVX) Stock Rating Upgraded by Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also issued reports on the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of GeoVax Labs in a research report on Monday, June 16th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research report on Wednesday, April 16th. Finally, Alliance Global Partners dropped their target price on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.10.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $0.94 on Friday. GeoVax Labs has a fifty-two week low of $0.73 and a fifty-two week high of $11.18. The stock has a market capitalization of $14.34 million, a PE ratio of -0.26 and a beta of 3.45. The business’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $1.54.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.14. GeoVax Labs had a negative return on equity of 511.96% and a negative net margin of 438.20%. The business had revenue of $1.64 million for the quarter, compared to analysts’ expectations of $0.75 million. On average, research analysts expect that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GOVX. Armistice Capital LLC acquired a new position in shares of GeoVax Labs during the 1st quarter worth approximately $703,000. Citadel Advisors LLC acquired a new position in shares of GeoVax Labs during the 4th quarter worth approximately $104,000. Geode Capital Management LLC increased its position in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the 1st quarter worth approximately $27,000. Finally, Northern Trust Corp acquired a new position in shares of GeoVax Labs during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.